EORTC studies with cisplatin and vindesine combination chemotherapy in advanced malignant melanoma and advanced breast cancer

SCOPUS: ar.jinfo:eu-repo/semantics/publishe

CHIMIOTHERAPIE DES TUMEURS NON SEMINOMATEUSES DU TESTICULE

During the past few years considerable progress has been achieved in the treatment of non-seminoma tumours of the testis, particularly since cisplatin was introduced. The use of this new drug in combination with other chemotherapeutic agents has resulted in complete remission in over 50% of all advanced cases, and many such remissions that have now persisted for more than 2 years will probably prove permanent. Thorough analysis of the various prognostic factors involved shows that the probability of response to new chemotherapeutic regimens mainly depends upon the extent of the disease and upon previous treatments. A prospective study of the value of platinum-containing drugs in the treatment of circumscribed tumours is currently under way.SCOPUS: ar.jinfo:eu-repo/semantics/publishe

European studies with adriamycin (NSC 123127) in lung cancer

European clinical trials in lung cancer involving adriamycin used alone or in combination with other agents are briefly reviewed. Adriamycin has clearly shown a definite efficacy against bronchogenic carcinoma apparently without cell type specificity, yet the survival is not markedly increased. An intermittent high dose schedule is well tolerated; however, this schedule does not seem to reduce the dose related cardiac toxic effects. No conclusive data are available with regard to the value of adriamycin in combination with other chemotherapeutic agents and with other treatment modalities.SCOPUS: ar.jinfo:eu-repo/semantics/publishe

La place de la chimiothérapie dans le traitement du cancer broncho pulmonaire

Single agent chemotherapy of advanced lung cancer is still unsatisfactory. The most encouraging results have been obtained with high dose intermittent treatment with cyclophosphamide, methotrexate or adriamycin. Combination chemotherapy is probably more efficacious than single agent chemotherapy, especially in oat cell carcinoma. The best treatment schedules give a response rate of approximately 80%. The value of adjuvant chemotherapy is not yet established, but new controlled clinical trials are indicated considering the poor results achieved by surgery and radiotherapy.SCOPUS: NotDefined.jinfo:eu-repo/semantics/publishe

La place de la chimiothérapie dans le traitement du cancer broncho pulmonaire

SCOPUS: ar.jinfo:eu-repo/semantics/publishe

PROLACTIN, LEVODOPA, AND MIGRAINE

SCOPUS: le.jinfo:eu-repo/semantics/publishe

Phase I trial of 9-hydroxy 2N-methyl ellipticinium (HME,NSC-264137) with a five-day schedule

SCOPUS: ar.jinfo:eu-repo/semantics/publishe

LE ROLE DU CISPLATINE DANS LA CHIMIOTHERAPIE D'AUJOURD'HUI

SCOPUS: NotDefined.jinfo:eu-repo/semantics/publishe

Phase I clinical trial of marcellomycin

SCOPUS: ar.jinfo:eu-repo/semantics/publishe

Phase I clinical study of 9-hydroxy-2N-methyl-ellipticinium acetate (NSC-264137) administered on a 5-day i.v. schedule

Twenty-three patients with advanced solid tumors received 9-hydroxy-2N-methyl-ellipticinium acetate at a single daily i.v. dose of 15-80 mg/m2 for 5 consecutive days, repeated every 3 weeks. One partial and one minor response were achieved in two patients with breast cancer. Dryness of the mouth was dose-related and dose-limiting. Local phlebitis was also dose-related and frequently severe at the highest dose levels. Other non-hematologic toxic effects were essentially mild to moderate and included nausea, vomiting, diarrhea, stomatitis, fever, weakness, transient renal and hepatic impairment, alopecia and chest pain. Minimal myelosuppression was encountered. It appears that 60 mg/m2/day is the maximum tolerated dose with a five-day schedule. According to our findings, this schedule does not seem to offer any advantage over the previously tested weekly administrations. © 1982.SCOPUS: ar.jinfo:eu-repo/semantics/publishe